Cationic Steroid Antimicrobial Compositions and Methods of Use

A method for treating a subject for poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of cationic steroid antimicrobial (CSA) to treat the subject for the poxvirus infection or pathogenesis.

A method for decreasing susceptibility of a subject to a poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of cationic steroid antimicrobial (CSA) to decrease susceptibility of the subject to a poxvirus infection or pathogenesis.

A method for decreasing or preventing an adverse side effect caused by vaccination of a subject with a poxvirus, comprising administering a sufficient amount of cationic steroid antimicrobial (CSA) to the subject to decrease or prevent an adverse side effect caused by vaccination with a poxvirus.

A method for providing a subject with protection against a poxvirus infection or pathogenesis, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to provide the subject with protection against the poxvirus infection or pathogenesis.

A method for decreasing or inhibiting poxvirus infection of a cell in vitro or in vivo, comprising administering a composition comprising a sufficient amount of cationic steroid antimicrobial (CSA) to inhibit poxvirus infection of the cell.

A method for treating a subject for a poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to treat the subject for the poxvirus infection or pathogenesis.

A method for decreasing susceptibility of a subject to a poxvirus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to decrease susceptibility of the subject to a poxvirus infection or pathogenesis.

A method for decreasing or preventing an adverse side effect caused by vaccination of a subject with a poxvirus, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to the subject to decrease or prevent an adverse side effect caused by vaccination with the poxvirus.

A method for identifying a candidate agent for treating a subject for a poxvirus infection or pathogenesis, comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) contacting said test agent with poxvirus and ascertaining whether the test agent inhibits poxvirus infection or pathogenesis, wherein a test agent identified as inhibiting poxvirus infection or pathogenesis is a candidate agent for treating a subject for poxvirus infection or pathogenesis.

A method for identifying a candidate agent for decreasing susceptibility of a subject to a poxvirus infection or pathogenesis, comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) contacting said test agent with poxvirus and ascertaining whether the test agent inhibits poxvirus infection or pathogenesis, wherein a test agent identified as inhibiting poxvirus infection or pathogenesis is a candidate agent for decreasing susceptibility of a subject to a poxvirus infection or pathogenesis.

A method for identifying a candidate agent for decreasing or preventing an adverse side effect caused by vaccination of a subject with or against a poxvirus, comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) contacting said test agent with poxvirus and ascertaining whether the test agent inhibits poxvirus infection or pathogenesis, wherein a test agent identified as inhibiting poxvirus infection or pathogenesis is a candidate agent for decreasing or preventing an adverse side effect caused by vaccination of a subject with or against a poxvirus.

A method for identifying a candidate agent for decreasing, inhibiting, ameliorating or preventing onset, severity, duration, progression, frequency or probability of one or more symptoms associated with poxvirus infection or pathogenesis, comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) administering said test agent to a subject infected with or exposed to poxvirus and ascertaining whether the test agent decreases, inhibits, ameliorates or prevents onset, severity, duration, progression, frequency or probability of one or more symptoms associated with poxvirus infection or pathogenesis, wherein a test agent identified is a candidate agent for decreasing, inhibiting, ameliorating or preventing onset, severity, duration, progression, frequency or probability of one or more symptoms associated with poxvirus infection or pathogenesis.